List view / Grid view
In an agreed merger with Mirati Therapeutics, Bristol Myers Squibb…
In an agreed merger with Mirati Therapeutics, Bristol Myers Squibb will gain rights to a best-in-class treatment for advanced non-small cell lung cancer (NSCLC) with a KRASG12C mutation.
Bristol Myers Squibb’s Sotyktu is the only TYK2 inhibitor approved…
Bristol Myers Squibb’s Sotyktu is the only TYK2 inhibitor approved for the treatment of any disease in the European Union.
The European Commission (EC) has approved Abecma, the first anti-BCMA…
The European Commission (EC) has approved Abecma, the first anti-BCMA CAR T-cell therapy for patients with multiple myeloma.
The US FDA has granted approval to BMS for Zeposia,…
The US FDA has granted approval to BMS for Zeposia, a once daily oral medication for the treatment of relapsing forms of multiple sclerosis.
The FDA has granted Breakthrough Therapy designation to Promacta for…
The FDA has granted Breakthrough Therapy designation to Promacta for use in combination with standard immunosuppressive therapy for severe aplastic anaemia...
